OTCM
NTBLQ
Market cap0kUSD
Feb 20, Last price
0.00USD
Name
Vascular Biogenics Ltd
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-41.60%
Rev. gr., 5y
-11.93%
Revenues
310k
+3,775.00%
Net income
-11m
L-21.82%
CFO
-14m
L+17.81%
Earnings
May 13, 2025
Profile
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 310 3,775.00% | 8 -97.19% | |||||||
Cost of revenue | 14,967 | 14,094 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (14,657) | (14,086) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,950) | 95 | |||||||
Tax Rate | |||||||||
NOPAT | (9,707) | (14,181) | |||||||
Net income | (11,264) -21.82% | (14,407) -10.25% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 22 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 523 | 361 | |||||||
Long-term debt | 3,575 | 361 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 163 | 40,465 | |||||||
Net debt | (7,727) | (859) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (13,716) | (11,642) | |||||||
CAPEX | (65) | (41) | |||||||
Cash from investing activities | 15,540 | 924 | |||||||
Cash from financing activities | 7,822 | 9,898 | |||||||
FCF | (15,572) | (13,400) | |||||||
| Balance | |||||||||
Cash | 11,825 | 1,581 | |||||||
Long term investments | |||||||||
Excess cash | 11,810 | 1,581 | |||||||
Stockholders' equity | (81,410) | (71,029) | |||||||
Invested Capital | 98,736 | 74,887 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 2,240 | 2,216 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (14,400) | (13,763) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||